Federal Circuit finds diagnostic test for Down's syndrome not patent-eligible

A method to assess the risk of fetal Down's syndrome is not patent-eligible subject matter, the U.S. Court of Appeals for the Federal Circuit has ruled, relying on recent high-profile cases about medical diagnostic patents.

This article requires free registration

This article requires free registration to The National Law Journal. Please sign in or register to read the full text.